



Jorge A. Goldstein David K.S. Comwe Michael Q. Lee teven R. Ludwig Lawrence B. Bugaisky Donald J. Featherstone Michael V. Messinger Judith U. Kim Patrick E. Garrett Jeffrey T. Helvey Heidi L. Kraus sa II Medler leffrey S. Weaver Kendrick P. Patterson Vincent L. Capuano Eldora Ellison Floyd Thomas C. Fiala Brian J. Del Buono Theodore A. Wood Elizabeth J. Haanes

Christine M. Lhulie George S. Bardn Daniel A. Klein* Tracy L. Muller Jon E. Wright LuAnne M. DeSantis A. Doyle

Nicole D. Dretai

Nancy J. Leith Aaron L. Schwartz Katrina Yujian Pei Quach Bryan L. Skelton Robert A. Schwartzman Teresa A. Cole¹¹ effrey S. Lundgren /ictoria S. Rutherford /lichelle K. Holoubek

Robert H. DeSelms Simon J. Elliott Julie A. Heider Mita Mukherjee Scott M. Woodhouse

Of Counsel Kenneth C. Bass III Evan R. Smith Marvin C. Guthrie

Admitted only in Maryland Admitted only in Virginia Practice Limited to Federal Agencies

June 9, 2005

WRITER'S DIRECT NUMBER: (202) 772-8625 INTERNET ADDRESS: ESTEFFE@SKGF.COM

Art Unit 1635

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Re:

U.S. Utility Patent Application

Application No. 10/725,015; Filed: December 2, 2003

Method for Producing Sterile Polynucleotide Based Medicaments

Inventors:

GEALL et al.

Our Ref:

1530.0610001/EKS/J-H

Sir:

Transmitted herewith for appropriate action are the following documents:

- 1. SKGF Cover Letter;
- 2. First Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97(b);
- Form PTO-1449, 1 page, listing 2 documents (AF3 and AG3); and 3.
- 4. One (1) return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Sterne, Kessler, Goldstein & Fox P.L.C. : 1100 New York Avenue, NW : Washington, DC 20005 : 202.371.2600 f 202.371.2540 : www.skgf.com

Commissioner for Patents June 9, 2005 Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Eric K. Steffe

Attorney for Applicants Registration No. 36,688

EKS/J-H/tis:awt

407720v1



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Confirmation No.: 3181

Geall et al.

Art Unit:

1635

Appl. No.: 10/725,015

Examiner:

Schnizer, R. A.

Filed: December 2, 2003

Atty. Docket: 1530.0610001/EKS/J-H

Method for Producing Sterile

Polynucleotide Based

Medicaments

First Supplemental Information Disclosure Statement Under 37 C.F.R. § 1.97(b)

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this First Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Information Disclosure Statement submitted June 6, 2005 in connection with the abovecaptioned application. In accordance with 37 C.F.R. § 1.98(a)(2), copies of U.S. patent documents AF3-AG3, cited on the attached Form PTO-1449, are not submitted.

The Examiner's attention is directed to the following co-pending, related applications:

U.S. Application No. 11/131,479, inventors Luke et al., filed May 18, 2005, now pending which is directed to related technical subject matter. A copy of co-pending U.S. Application No: 11/131,479 is not provided pursuant to the Waiver of Requirements in 37 C.F.R. § 1.98, Official Gazette, October 16, 2004. The identification of this U.S. Patent Application is not to be construed as a waiver of secrecy as to those applications now or upon issuance of the present application as a patent.

The Examiner is respectfully requested to consider the cited application and the art cited therein during examination.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed Form PTO-1449, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Eric K. Steffe

Attorney for Applicants Registration No. 36,688

Date:

1100 New York Avenue, N.W. Washington, D.C. 20005-3934 (202) 371-2600

406987_1.DOC

	مر جي			ATTY. DOCKET NO.		APPLICATION NO.	Page 1 of 1	
FORM PTO-1449 SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT				1530.0610001/EKS/J-H FIRST NAMED INVENTOR		10/725,015		
				Geall et al. FILING DATE ART UNIT				
TRADE	Mar	STATEMENT		December 2, 2003		1635		
EXAMINER		DOCUMENT		ATENT DOCUMENTS			T	
INITIAL	AA	NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE	
	AB						<u> </u>	
	AC							
	AD							
	AE							
	AF3	5,994,317	11/30/1999	Wheeler			04/09/1996	
	AG3	6,875,748 B2	04/05/2005	Manthorpe et al.			04/23/2001	
	AH							
	AI							
	AJ							
	AK							
EXAMINER		LDOCUMENT	FOREIGN	PATENT DOCUMENT	S		- 	
INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
							Yes No	
	AM				-		Yes No	
	AN						Yes No	
	AO						Yes No	
	AP						Yes No	
		OTHER	(Including Aut	hor, Title, Date, Pertine	ent Pages, etc	;.)		
	AR							
	AS							
	AT							
EXAMINER					DAT	DATE CONSIDERED		
EXAMINER: In	nitial if refer	rence considered, wh	nether or not citation	is in conformance with MPEF	P 609. Draw line to	hrough citation if no	ot in conformance	
and not conside 406997_1.DOC	sieu. indu	de copy of this form	with next communic	аноп то Аррисапт.		S	KGF Rev. 12/03/03	